forY now, most people have come to accept a resignation when it comes to Covid-19. We accept that we will likely get injured at some point during the respiratory disease season – and when we do so, we will feel the disease for a few days, then we exceed it.
But what if you can avoid Covid-19?
This is the potential promise of a new study on a drug presented by the Japanese pharmaceutical company Shionogi. At a scientific conference in San Francisco, researchers I mentioned Their medicine, ENSITLVIR, helped prevent people who were exposed to SARS-COV-2 from a positive test of the disease.
There is currently no approved drug to prevent Covid-19, but ENSITLVIR has already agreed in Japan as a treatment for Covid-19. It reduces hospital for Covid-19 among people who wear a risk of complications; For the least vulnerable, it reduces the number of days when symptoms are sick. The US Food and Drug Administration is studying the drug to agree to the rapid path as a way to prevent Covid-19, based on this recent study presented at the Conference of Viruses and opportunistic infections. (The study has not yet been published in the Journal of Laysee.)
The researchers studied more than 2,300 people at the age of 12 and over who had no Covid-19 but they lived with someone who had a positive test at the time of the study. Then they were randomly appointed to receive either ENSITLVIR or imaginary pills for five days. Everyone began studying to take birth control pills once a day within three days that their colleague at home had been reported about the symptoms of Covid-19.
Among those who took ENSITRELVIR, about 3 % ended with the development of Covid-19, compared to 9 % of those who take the toxic goal. It turned out that about 10 % of the family members in the person who initially tested positively were also positive, even if they did not suffer from symptoms and did not realize that they were positive – which highlights the extent of the transmission of the virus, and the importance of protecting people from obtaining infection. The results mean that the drug reduces the risk of obtaining Covid-19 by 67 %.
The idea of using an antiviral treatment to protect people at risk of infection is not new. Oseltamivir, or Tamiflu, is present 84 % effective In protecting people from getting influenza when someone else is in his home. But when scientists have studied antiviral treatments for Covid-19, such as Paxlovid and Molnupiravir, they did not find the same preventive benefits.
Read more: When is Tamiflu worth taking?
“This study is the first to be this strategy [to prevent COVID-19] “It has been documented for success,” says Dr. Friedrich Hayden, a professor of high medicine at the University of Virginia University, who presented the data at the conference.
Finding a way to prevent Covid-19 is very important, especially for older adults and people with immunodeficiency and others who are at risk of complications. In the study, people in this category who were taking the drug reduced the risk of getting Covid-19 by 76 %. Avoid infection also allows people to avoid complications such as Coveyd longWhich is not yet many treatments.
Since ENSITRELVIR works by preventing the ability of the virus to make more copies themselves, it is logical that it can treat and prevent the disease, depending on when people take it. The dose to treat Covid-19 is the same dose used in the study to prevent the disease. If ENSITLVIR is taking early-with three days of being closely exposed to a person who suffers from the virus-the drug can effectively hinder SARS-COV-2 enough to prevent him from injuring many cells. If people take it after their injury, the drug can help reduce the amount of viruses that the immune system must manage and can reduce the chances of severe diseases.
“This is really aware of my knowledge, the first documents can use an oral antiviral to prevent Covid-19 in places of high risk transmission such as families,” says Hayden.
